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Adrenal metastases are a common ﬁnding in metastatic lung and breast cancer. Often there are no clinical symptoms suggesting
them. In this paper, we present a case of a 66-year-old man with metastatic lung cancer suﬀering from severe hyperkaliemia due to
hypoaldosteronism as a result of bilateral adrenal metastasis.
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1.Introduction
Hyperkalemia most often is caused by potassium retention
due to renal insuﬃciency. A rare cause of hyperkalemia
is adrenal insuﬃciency induced by adrenal metastasis. The
latter is found in metastatic lung cancer in up to 40 to 60
percent, however in the majority of patients without clinical
signiﬁcance.
2.CaseReport
A 66-year-old man was admitted to the hospital due to
symptomatic bradycardia and a progressive generalized
muscularweaknessstartingtwodaysearlier.Hehadahistory
of metastatic nonsmall lung cancer (type adenocarcinoma),
since 15 months. In addition coronary artery disease was
known for two years. Initial chemotherapy with carboplatin
and gemcitabine was initiated and transiently a good tumor
responsewasachieved.Theprimarytumorandthemediasti-
nallymphnodesprogressedandthustreatmentwasswitched
to a tyrosine kinase-inhibitor therapy with erlotinib. Due
to side eﬀects (muscular weakness of the limbs), the
therapy was discontinued fourteen weeks later although
having stabilized the disease and the symptoms resolved
completely.
At the actual presentation physical examination revealed
a bradycardia (40/min), normal blood pressure, and
tetraparesis. The cranial nerves responded normal. The skin
color was tanned even at sites not being exposed to the
sunlight.
Laboratory analysis demonstrated severe hyperkalemia
of 8.8mmol/L, mild hyponatremia (132mmol/L), and
metabolic acidosis (pH 7.2) found. A rise in creatinine
(127µmol/L) and serum urea (21.4mmol/L) level was
seen for the ﬁrst time. The electrocardiogram conﬁrmed
sinusbradycardia with broad QRS complexes.
No obvious cause for hyperkalemia was present (e.g.,
chronic renal insuﬃciency, potassium release from cells due
to rhabdomyolysis or tumor lysis) a low dose ACTH stim-
ulation test [1] revealed an insuﬃcient cortisone response
(184nmol/L). A low aldosterone level (0.10nmol/L) and an
elevated plasma renin activity (33.7mU/L) conﬁrmed the
initial hypothesis of hypoaldosteronism. Since the patient
hadnoobviouscauseforhypoadrenalism(suchaslong-term
corticosteroid therapy, infection, autoimmune disorder), we
suggested the adrenal metastases shown by a computed
tomography scanning (Figure 1) being the cause for adrenal
insuﬃciency.
After substitution of ﬂuids and hydrocortisone as well
as administration of insulin and glucose, sodium bicar-
bonate, salbutamol, furosemide, and cation exchange resin,
the patient improved rapidly. The tetraparesis disappeared
totally, and heart rate rose to normal. Serum potassium
concentration and pH level normalized and stayed stable
under hydrocortisone administration.
3. Discussion
The prevalence of Addison’s disease has been estimated at 35
to 120 per million [2–4]. At the time when Thomas Addison2 Journal of Oncology
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Figure 1
in 1855 reported about the “disease of the suprarenal
capsules” most of the cases were caused by disseminated
tuberculosis [5]. Today autoimmune adrenalitis counts for
70–90 percent of the cases, tuberculosis is responsible for 7–
20 percent and the residual is caused by adrenal hemorrhage
orinfarction,drugs,andsuppressionbymetastaticcancer[6,
7]o rl y m p h o m a[ 8–11]. Autopsy studies suggest inﬁltration
of the adrenal glands by metastatic cancer being a common
ﬁnding. It is demonstrated in up to 40–60 percent of patients
with disseminated lung or breast cancer [6, 7], probably
because of their rich blood supply. Apparently clinical
adrenal insuﬃciency is rarely reported though there are few
reports about Addisonian crisis due to metastatic adrenal
inﬁltrationbylungcancerorlymphoma[12–15].Somecases
might be missed because other causes are explaining reduced
general conditions and hyperkalemia such as impaired renal
function and potassium sparing diuretics. Unfortunately
there are only unimpressive signs and symptoms suggest-
ing adrenal insuﬃciency. Typically patients present with
generalised weakness, fatigue, gastrointestinal complaints,
dehydration, postural hypotension, and—in case of adrenal
crisis—shock [16]. Characteristic is a hyperpigmentation,
which is evident in nearly all patients with primary adrenal
insuﬃciency [17]. Hyponatremia is found in 85 percent
of patients, and hyperkalemia often associated with a mild
hyperchloremic acidosis occurs in 60 percent of cases.
4.LearningPoint
In patients with metastatic lung cancer adrenal metastasis
is frequent however symptoms are rare. However, hyper-
kalemia may be the result of adrenal insuﬃciency due to
adrenal metastasis, which can easily be revealed by low-dose
ACTH testing.
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